Willow Biosciences Past Earnings Performance
Past criteria checks 0/6
Willow Biosciences has been growing earnings at an average annual rate of 16%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 78% per year.
Key information
16.0%
Earnings growth rate
44.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 78.0% |
| Return on equity | -379.2% |
| Net Margin | -1,111.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Willow Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -13 | 6 | 0 |
| 30 Sep 23 | 2 | -15 | 8 | 0 |
| 30 Jun 23 | 1 | -17 | 9 | 0 |
| 31 Mar 23 | 1 | -17 | 10 | 0 |
| 31 Dec 22 | 1 | -15 | 9 | 0 |
| 30 Sep 22 | 0 | -15 | 9 | -9 |
| 30 Jun 22 | 0 | -7 | 9 | -6 |
| 31 Mar 22 | 0 | 2 | 9 | -3 |
| 31 Dec 21 | 0 | -6 | 9 | 0 |
| 30 Sep 21 | 0 | -16 | 7 | 11 |
| 30 Jun 21 | 0 | -27 | 7 | 9 |
| 31 Mar 21 | 0 | -44 | 6 | 8 |
| 31 Dec 20 | 0 | -34 | 6 | 7 |
| 30 Sep 20 | 0 | -22 | 8 | 6 |
| 30 Jun 20 | 0 | -16 | 8 | 6 |
| 31 Mar 20 | 0 | -45 | 10 | 4 |
| 31 Dec 19 | 0 | -45 | 8 | 3 |
| 30 Sep 19 | 0 | -42 | 5 | 2 |
| 30 Jun 19 | 0 | -41 | 4 | 0 |
| 31 Mar 19 | 0 | -2 | 2 | 0 |
| 31 Dec 18 | 0 | -2 | 2 | 0 |
| 30 Sep 18 | 0 | -2 | 2 | 0 |
| 31 Dec 17 | 0 | -2 | 2 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Quality Earnings: CANS.F is currently unprofitable.
Growing Profit Margin: CANS.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CANS.F is unprofitable, but has reduced losses over the past 5 years at a rate of 16% per year.
Accelerating Growth: Unable to compare CANS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CANS.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CANS.F has a negative Return on Equity (-379.19%), as it is currently unprofitable.